Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
STRO Sutro Biopharma Inc
- Stocks
- Healthcare
- NASDAQ: STRO
Price (delayed)
$0.9116
Market cap
$76.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.98
Enterprise value
-$8.7M
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
Highlights
The company's debt fell by 24% YoY and by 8% QoQ
The gross profit has plunged by 57% YoY but it has grown by 7% from the previous quarter
Sutro Biopharma's revenue has shrunk by 57% YoY but it has increased by 7% QoQ
The equity has dropped by 158% since the previous quarter and by 126% year-on-year
STRO's net income has plunged by 113% YoY and by 8% from the previous quarter
Key stats
What are the main financial stats of STRO
Market
Valuations
Earnings
Shares outstanding
84.46M
Market cap
$76.99M
Enterprise value
-$8.7M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.13
Revenue
$66.43M
Gross profit
$66.43M
Operating income
-$250.38M
Net income
-$245.22M
EBIT
-$218.53M
EBITDA
-$205.86M
Free cash flow
-$198.51M
Per share
Balance sheet
Liquidity
EPS
-$2.98
EPS diluted
-$2.98
Free cash flow per share
-$2.39
Book value per share
-$0.31
Revenue per share
$0.8
TBVPS
$3.87
Total assets
$321.43M
Total liabilities
$347.24M
Debt
$21.4M
Equity
-$25.81M
Working capital
$154.36M
Debt to equity
-0.83
Current ratio
2.16
Quick ratio
1.98
Net debt/EBITDA
0.42
Margins
Efficiency
Dividend
EBITDA margin
-309.9%
Gross margin
100%
Net margin
-369.1%
Operating margin
-376.9%
Return on assets
-59.5%
Return on equity
-347.6%
Return on invested capital
-133.7%
Return on capital employed
-116%
Return on sales
-328.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
STRO stock price
How has the Sutro Biopharma stock price performed over time
Intraday
3.77%
1 week
4.6%
1 month
68.81%
1 year
-78.03%
YTD
-50.46%
QTD
40.12%
Financial performance
How have Sutro Biopharma's revenue and profit performed over time
Revenue
$66.43M
Gross profit
$66.43M
Operating income
-$250.38M
Net income
-$245.22M
Gross margin
100%
Net margin
-369.1%
STRO's operating income has dropped by 142% year-on-year and by 5% since the previous quarter
STRO's net income has plunged by 113% YoY and by 8% from the previous quarter
The gross profit has plunged by 57% YoY but it has grown by 7% from the previous quarter
Sutro Biopharma's revenue has shrunk by 57% YoY but it has increased by 7% QoQ
Price vs fundamentals
How does STRO's price correlate with its fundamentals
Growth
What is Sutro Biopharma's growth rate over time
Valuation
What is Sutro Biopharma stock price valuation
P/E
N/A
P/B
N/A
P/S
1.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.13
STRO's EPS has plunged by 59% YoY
The equity has dropped by 158% since the previous quarter and by 126% year-on-year
The stock's price to sales (P/S) is 83% less than its 5-year quarterly average of 6.7 and 29% less than its last 4 quarters average of 1.6
Sutro Biopharma's revenue has shrunk by 57% YoY but it has increased by 7% QoQ
Efficiency
How efficient is Sutro Biopharma business performance
STRO's return on assets has dropped by 129% year-on-year and by 13% since the previous quarter
Sutro Biopharma's ROE has plunged by 55% from the previous quarter
STRO's return on invested capital is down by 40% since the previous quarter
STRO's ROS is down by 2.4% from the previous quarter
Dividends
What is STRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for STRO.
Financial health
How did Sutro Biopharma financials performed over time
STRO's total assets is 7% smaller than its total liabilities
The quick ratio has plunged by 54% YoY and by 20% from the previous quarter
Sutro Biopharma's current ratio has plunged by 52% YoY and by 17% from the previous quarter
The company's debt is 183% higher than its equity
The equity has dropped by 158% since the previous quarter and by 126% year-on-year
The company's debt fell by 24% YoY and by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.